Your browser doesn't support javascript.
loading
SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
Tara M Narowski; Kristin Raphel; Lily E Adams; Jenny Huang; Nadja A Vielot; Ramesh Jadi; Aravinda M de Silva; Ralph S Baric; John E Lafleur; Lakshmanane Premkumar.
Afiliação
  • Tara M Narowski; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
  • Kristin Raphel; Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA.
  • Lily E Adams; Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27
  • Jenny Huang; Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA.
  • Nadja A Vielot; Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
  • Ramesh Jadi; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
  • Aravinda M de Silva; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
  • Ralph S Baric; Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27
  • John E Lafleur; Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA.
  • Lakshmanane Premkumar; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-449100
ABSTRACT
With the advance of SARS-CoV-2 vaccines, the outlook for overcoming the global COVID-19 pandemic has improved. However, understanding of immunity and protection offered by the SARS-CoV-2 vaccines against circulating variants of concern (VOC) is rapidly evolving. We investigated the mRNA vaccine-induced antibody responses against the referent WIV04 (Wuhan) strain, circulating variants, and human endemic coronaviruses in 168 naive and previously infected people at three-time points. Samples were collected prior to vaccination, after the first and after the second doses of one of the two available mRNA-based vaccines. After full vaccination, both naive and previously infected participants developed comparable robust SARS-CoV-2 specific spike IgG levels, modest IgM and IgA binding antibodies, and varying degrees of HCoV cross-reactive antibodies. However, the strength and frequency of neutralizing antibodies produced in naive people were significantly lower than in the previously infected group. We also found that 1/3rd of previously infected people had undetectable neutralizing antibodies after the first vaccine dose; 40% of this group developed neutralizing antibodies after the second dose. In all subjects neutralizing antibodies produced against the B.1.351 and P.1 variants were weaker than those produced against the reference and B.1.1.7 strains. Our findings provide support for future booster vaccinations modified to be active against the circulating variants.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...